|
Press Releases |
|
|
|
Wednesday, May 9, 2018 |
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
Friday, April 20, 2018 |
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
Tuesday, April 17, 2018 |
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
Wednesday, March 28, 2018 |
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
Friday, March 2, 2018 |
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
Tuesday, October 17, 2017 |
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
Friday, September 9, 2016 |
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Mailbird Expands to Mac: Popular Windows Email Client Launches Much-Anticipated Mac App
Nov 22, 2024 18:30 HKT/SGT
|
|
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs Q4 2024 Report
Nov 22, 2024 17:42 JST
|
|
|
DesignInspire opens on December 5, with free admission for the public
Nov 22, 2024 15:30 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 22, 2024 15:00 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 22, 2024 14:42 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 22, 2024 14:41 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 12:00: JST
|
|
|
Daeshin MC Co., Ltd.は、産業現場から公共施設まで快適な室内環境を作り出すクリーンソリューションを発表
Nov 22, 2024 12:00: JST
|
|
|
三菱重工、新たな防衛輸送用「機動舟艇」に搭載するウォータージェット推進装置の供給へ
Nov 22, 2024 11:45: JST
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2%
Nov 22, 2024 10:00 HKT/SGT
|
|
|
アレス・マネジメント、東京オフィス開設でアジア事業を拡充
Nov 22, 2024 09:00: JST
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|